Tenofovir

nChroma Bio, formed by Chroma Medicine and Nvelop Therapeutics, secured $75M to develop CRMA-1001, a liver-targeted epigenetic editing therapy for chronic hepatitis B and D. Preclinical studies show CRMA-1001's potential to silence HBV biomarkers durably, offering superior cure rates. Chronic HBV and HDV remain global health issues, highlighting the need for advanced therapies.

Developing drug combinations for diseases like cancer faces challenges due to multiple molecular pathways and regulatory hurdles. The FDA and EMA evaluate combinations based on safety and efficacy, with flexibility in initial trials. Dose-ranging and efficacy of individual components are generally expected before codevelopment. Examples of NCE combinations exist, but each case is evaluated based on provided evidence. Computational methods aid in identifying effective combinations and predicting safety, though human safety predictions remain complex.

NIH launches trial to assess safety and acceptability of a rectal microbicide douche containing tenofovir for HIV prevention among men who have sex with men. The study will compare this 'on-demand' method with oral PrEP, enrolling 150 participants across eight U.S. sites.

NIH launches trial to test safety and acceptability of a rectal microbicide douche containing tenofovir for HIV prevention among men who have sex with men. The study, HPTN 106, will compare the microbicide douche with oral PrEP over two two-month periods, assessing acceptability, adherence, and preference. The trial aims to expand HIV prevention options for at-risk populations.

IOCB Prague launches a new lab in Boston, aiming to become an outpost for Czech science abroad, with a focus on medicinal chemistry and technology transfer. The branch, supported by private donations and IOCB revenues, plans to expand with additional research labs.

Salim and Quarraisha Abdool-Karim won the Lasker Prize for their HIV research, focusing on heterosexual transmission and developing Tenofovir gel to prevent HIV in women. Their work contributed to reducing new HIV infections in South Africa.